Dear Editor,Blockade of PD-1/PD-L1 signaling pathway by monoclonal antibodies(MAbs)to release the anti-tumor activity of pre-existing tumor specific T cell immunity has initiated a new era for tumor immunotherapy.Admi...Dear Editor,Blockade of PD-1/PD-L1 signaling pathway by monoclonal antibodies(MAbs)to release the anti-tumor activity of pre-existing tumor specific T cell immunity has initiated a new era for tumor immunotherapy.Administration of anti-PD-1 MAbs(nivolumab and pembrolizumab)in either monotherapy or in combination with anti-CTLA-4 MAbs or traditional chemother-apy has achieved a tumor regression rate of 30%-50%in dealing with melanoma,non-small cell lung cancer,etc.(Larkin et al.,2015).展开更多
基金This work was supported by the National Natural Science Founda-tion of China(Grant Nos.31390432 and 31500722)the National Basic Research Program(973 Program)(NO.2013CB531502)+1 种基金We also thank Yuanyuan Chen and Zhenwel Yang from Institute of Biophysics,Chinese Academy of Sciences for their technical support in the SPR assayG.F.G.is a leading prinoiple Investigator of NSFC Innovative Research Group(Grant No.81621091).
文摘Dear Editor,Blockade of PD-1/PD-L1 signaling pathway by monoclonal antibodies(MAbs)to release the anti-tumor activity of pre-existing tumor specific T cell immunity has initiated a new era for tumor immunotherapy.Administration of anti-PD-1 MAbs(nivolumab and pembrolizumab)in either monotherapy or in combination with anti-CTLA-4 MAbs or traditional chemother-apy has achieved a tumor regression rate of 30%-50%in dealing with melanoma,non-small cell lung cancer,etc.(Larkin et al.,2015).
